These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17310321)

  • 1. Manufacture of recombinant polyclonal antibodies.
    Rasmussen SK; Rasmussen LK; Weilguny D; Tolstrup AB
    Biotechnol Lett; 2007 Jun; 29(6):845-52. PubMed ID: 17310321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of target-specific recombinant human polyclonal antibodies in mammalian cells.
    Wiberg FC; Rasmussen SK; Frandsen TP; Rasmussen LK; Tengbjerg K; Coljee VW; Sharon J; Yang CY; Bregenholt S; Nielsen LS; Haurum JS; Tolstrup AB
    Biotechnol Bioeng; 2006 Jun; 94(2):396-405. PubMed ID: 16596663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of mass spectrometry based techniques for the identification and determination of compositional variability in recombinant polyclonal antibody products.
    Persson P; Engström A; Rasmussen LK; Holmberg E; Frandsen TP
    Anal Chem; 2010 Sep; 82(17):7274-82. PubMed ID: 20690610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle.
    Haurum J; Bregenholt S
    IDrugs; 2005 May; 8(5):404-9. PubMed ID: 15883923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal anti-D IgM--analysis and comparison with polyclonal antisera].
    Hitzler W
    Beitr Infusionsther; 1988; 21():272-5. PubMed ID: 2462991
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents.
    Montano RF; Penichet ML; Blackall DP; Morrison SL; Chintalacharuvu KR
    J Immunol Methods; 2009 Jan; 340(1):1-10. PubMed ID: 18848836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacturing of recombinant therapeutic proteins in microbial systems.
    Graumann K; Premstaller A
    Biotechnol J; 2006 Feb; 1(2):164-86. PubMed ID: 16892246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and manufacture of monoclonal antibodies for radioimmunotherapy.
    Hale G; Berrie E; Bird P
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):258-66. PubMed ID: 15640789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
    Haurum JS
    Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody production: polyclonal-derived biotherapeutics.
    Newcombe C; Newcombe AR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):2-7. PubMed ID: 16893686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and characterization of monoclonal and polyclonal antibodies against human intestinal fatty acid-binding protein (I-FABP) using synthetic regional peptides and recombinant I-FABP.
    Kajiura S; Yashiki T; Funaoka H; Ohkaru Y; Nishikura K; Kanda T; Ajioka Y; Igarashi M; Hatakeyama K; Fujii H
    J Immunoassay Immunochem; 2008; 29(1):19-41. PubMed ID: 18080878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody production without animals.
    Stadler BM
    Dev Biol Stand; 1999; 101():45-8. PubMed ID: 10566774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant polyclonal antibodies for cancer therapy.
    Sharon J; Liebman MA; Williams BR
    J Cell Biochem; 2005 Oct; 96(2):305-13. PubMed ID: 16052504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recombinant expression of human fibrogenic factors and preparation of polyclonal antibodies].
    Chen XH; Cai GP
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Oct; 23(10):950-2. PubMed ID: 17908507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies produced against antigenic determinants present in complex mixtures of proteins.
    King SW; Morrow KJ
    Biotechniques; 1988 Oct; 6(9):856-61. PubMed ID: 2483507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.
    Kumpel BM
    Vox Sang; 2007 Aug; 93(2):99-111. PubMed ID: 17683353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies and genetically engineered related molecules: production and purification.
    Roque AC; Lowe CR; Taipa MA
    Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies and gene therapy: teaching old 'magic bullets' new tricks.
    Sanz L; Blanco B; Alvarez-Vallina L
    Trends Immunol; 2004 Feb; 25(2):85-91. PubMed ID: 15102367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature?
    Dinnis DM; James DC
    Biotechnol Bioeng; 2005 Jul; 91(2):180-9. PubMed ID: 15880827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody cocktails: next-generation biopharmaceuticals with improved potency.
    Logtenberg T
    Trends Biotechnol; 2007 Sep; 25(9):390-4. PubMed ID: 17681390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.